Navigation Links
Metabolic Solutions Development Company Awarded Funding by The Michael J. Fox Foundation
Date:2/7/2013

KALAMAZOO, Mich., Feb. 7, 2013 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) announced today that it has received an award from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to conduct preclinical research on a first-in-class mTOT Modulator, MSDC-0160, as a potential treatment for levodopa induced dyskinesia (LID). The study will be undertaken in collaboration with Patrik Brundin , MD, PhD, of Van Andel Institute (VAI).

The aim of the study, titled "Potential of Novel Insulin Sensitizers to Treat Dyskinesia," is to determine if MSDC-0160 can prevent or reverse LID in a preclinical model of Parkinson's disease (PD). Should the results show that MSDC-0160 can significantly modify LID in vivo, MSDC plans to begin a clinical trial to examine the effects of MSDC-0160 in PD patients with LID. Such a clinical trial could begin in 2014.

MSDC-0160
MSDC-0160 is a novel once-a-day oral insulin sensitizer and the first in a new class of therapeutic agents called mTOT Modulators. mTOT™ is newly identified protein complex in the inner mitochondrial membrane that appears to function as a molecular "sensor switch" that coordinates carbohydrate, lipid, and amino acid metabolism. MSDC-0160 selectively modulates proteins in the mTOT complex, effecting pyruvate utilization and resulting in improved insulin action, lipid oxidation, preservation of beta cell function, and generation of brown fat, an important organ in the control of body composition. In a recently completed Phase 2b clinical trial in 258 patients with type 2 diabetes, MSDC-0160 was shown to lower hemoglobin A1c significantly without the side effect profile of Actos®. The compound is also currently being studied in a pilot Phase 2a trial in patients with dementia due to Alzheimer's disease (NCT01374438).

About Parkinson's Disease
Over one million people in the US and an estimated
'/>"/>

SOURCE Metabolic Solutions Development Company, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Metabolic Solutions Development Company announces publication of Phase 2b data in Clinical Pharmacology & Therapeutics
2. Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
3. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
4. Profil Institute Partners with Florida Hospital to Establish East Coast Center for Clinical Metabolic Research
5. New Wellness Products with Results that Identify Healthiness, Deficiencies and Solutions
6. H. D. Smith Specialty Solutions Appoints 20-year Industry Veteran Tim Booth To Executive Vice President, Smith Medical Partners
7. BioLife Solutions Appoints Rick Stewart To Board of Directors
8. New Findings Offer Systemic Solutions to Address Non-communicable Diseases (NCDs) in Low- and Middle-income Countries
9. Omnicell to Showcase Automation Solutions at Arab Health 2013
10. Elekta to Showcase Broad Portfolio of Cancer Management Solutions at 2013 Arab Health Congress and Exhibition
11. H. D. Smith Establishes Specialty Solutions Organization And Realigns Senior Leadership To Support Growing Geographic Reach, Diversified Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... India , September 4, 2015 ... Market by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) ... Technology and by Product - Global Forecast to 2020", ... to reach USD 2.5 Billion by 2020, growing at ... 2015 to 2020. Browse 139 Tables ...
(Date:9/4/2015)... 4, 2015  Allergan plc (NYSE: AGN ) a ... , CEO and President of Allergan, will provide an overview ... Global Healthcare Conference 2015 in New York, NY ... The presentation will take place on Thursday, September ... Hyatt New York, 109 East 42nd Street, New ...
(Date:9/4/2015)... Research and Markets ... the "Veterinary Pharmaceutical Submissions in the EU ... to their offering. This practical two-day ... constituent parts of the application for marketing authorisation ... marketing authorisation is sought in the European Union, ...
Breaking Medicine Technology:Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 2Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 3Veterinary Pharmaceutical Submissions in the EU: Two day Course - London, UK - December 7-8, 2015 2
... Expanding its offering of passive safety devices to protect ... Braun Medical Inc. (B. Braun) recently announced that the ... of the company,s Introcan Safety ® 3 Closed ... Safety ® IV Catheter. B. Braun made the ...
... is well known that ophthalmologists around the world often ... (AMD) over the approved treatment Lucentis (ranibizumabintravitreal) due to ... efficacy. AMD Alliance International (AMDAI) is ... of a concerning surge in eye infections over the ...
Cached Medicine Technology:Safety to the Power of Three: B. Braun Medical Inc. Announces Introcan Safety® 3 Closed IV Catheter 2AMD Alliance, Representing AMD Patient Organizations Globally, Encourages Health Care Providers to Stop Using Avastin for Off-Label Ocular Use 2AMD Alliance, Representing AMD Patient Organizations Globally, Encourages Health Care Providers to Stop Using Avastin for Off-Label Ocular Use 3
(Date:9/4/2015)... , ... September 04, 2015 , ... ... CEREC technology is now available at CitiDent. CEREC is a newer method for ... to saving time for patients by eliminating the need for multiple appointments, CEREC ...
(Date:9/4/2015)... Pittsburgh, PA (PRWEB) , ... September 04, 2015 , ... Many consumers are looking for ... Cups could be their solution. , The patent-pending K Med Cups provide a quick and ... they help to relieve a cold, flu or cough. As a result, they enhance comfort ...
(Date:9/4/2015)... ... September 04, 2015 , ... The conference ... in Hollywood, Florida October 9-10, 2015 at the Diplomat Resort & Spa has ... are doctors and researchers at the top of their field and will be ...
(Date:9/4/2015)... ... , ... Lalonde Gordon ran a 44.64 seconds scorcher in the third and ... 400 meters final, with an impressive 44.89 seconds at the 2015 North American, Central ... in August 2015. The 44.64 time is a new NACAC Championship record. , ...
(Date:9/4/2015)... ... September 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... details involving the Pope’s upcoming trip to the United States. , Yisrayl lays out what ... with the Vatican and society is. Yisrayl also provides the meaning of his own name ...
Breaking Medicine News(10 mins):Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2
... , , , SILVER SPRING, ... Wellness Center has selected Artefill, the first and only FDA-approved microsphere-enhanced ... who are looking for a longer lasting dermal filler. Dr. Gonzalez ... to its proven success and effectiveness for the correction of wrinkles. ...
... , , WASHINGTON, Aug. 24 ... Veterans Affairs (VA) is taking steps to assist Veterans seeking compensation ... hidden wounds of war are being addressed vigorously and comprehensively by ... the 21st century," said Secretary Shinseki. , , ...
... , , , , ... the most powerful person in healthcare by readers of Modern ... whose name has become inextricably linked with healthcare reform, topped the ... , , "Think about healthcare reform. Now, try ...
... AUBURN HILLS, Mich., Aug. 24 ... leader in the discovery and development of nanotechnology-enabled, ultraviolet-curable ... collaboration agreement with a major tobacco company for the ... (FSC) cigarettes. FSC cigarettes are designed to meet government ...
... , , , EMERYVILLE, Calif., ... , Inc. (NYSE-Amex: NBY ), a clinical stage ... a wide range of bacterial, viral, and fungal infections, announced today ... the 47th Annual Meeting of the Infectious Diseases Society of America ...
... , ABBOTT PARK, Ill., Aug. 24 ... has received approval from Health Canada for the XIENCE V(R) Everolimus ... (CAD). XIENCE V is the only drug eluting stent to have ... the primary endpoints of two randomized, pivotal (phase III) clinical trials. ...
Cached Medicine News:Health News:Benjamin S. Gonzalez, MD Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 2Health News:Benjamin S. Gonzalez, MD Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 3Health News:Secretary Shinseki Moves to Simplify PTSD Compensation Rules 2Health News:Obama Named the Most Powerful Person in Healthcare 2Health News:Ecology Coatings Signs Development Agreement with Major U.S. Tobacco Company 2Health News:Ecology Coatings Signs Development Agreement with Major U.S. Tobacco Company 3Health News:NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting 2Health News:NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting 3Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 2Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 3Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 4Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 5
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: